Description
The market for psychotherapeutics drugs is about to change dramatically — and serious pharmaceutical market watchers will want to be prepared. Kalorama’s Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs: World Market is the most exhaustive guide available to this booming market and the direction it is headed in the next four years.
Psychotherapeutics treat conditions classified as abnormal behavior, thoughts and feelings that persist for a determined amount of time causing distress or emotional/physical impairment. Depression, anxiety, psychosis, ADHD and nicotine and drug dependence are among the conditions psychotherapeutics treat. Well-known brands such as Prozac™, Zoloft™ and Ritalin ™ have made this a $37 billion market. And according to Kalorama’s research, revenues from this area will grow more than 50% by 2010.
Antidepressants, Antipsychotics, Antianxiety Drugs, and other Psychotherapeutics: World Marketcovers this market completly including an overview; surveys of the key corporate players, geographic market breakdowns, and revenue forecasts to 2010 in these key market segments:
- Antidepressants
- Antipsychotics/Antimanics
- Antianxiety Drugs
- Stimulants and Non-stimulants for ADHD
- Smoking Cessation Drugs, Drug Addiction Treatments, Eating Disorder Treatments and Other Psychotherapeutics
In every category of psychotherapeutics, new competitors are emerging. Kalorama’s report provides profiles of thirty-six new psychotherapeutic drugs in the pipeline, their expected approval status, and how they may shake up the marketplace – as well as a complete discussion of the issues and trends that will effect psychotherapeutics.
The report also includes current issues and trends affecting the industry including the increasing number of additional indications pharma companies are seeking for their brands and success stories in this area.
Over 110 tables and figures clearly demonstrate the current and future psychotherapeutic markets.
As part of our complete coverage, the following companies are profiled:
- Astellas Pharma, Inc.
- AstraZeneca Plc
- Biovail Corporation
- Bristol-Myers Squibb
- Eli Lilly & Company
- Forest Laboratories, Inc.
- GlaxoSmithKline Plc
- H. Lundbeck A/S
- Johnson & Johnson
- Otsuka Pharmaceutical Co. Ltd.
- Pfizer, Inc.
- Shire Pharmaceuticals Group Plc
- Wyeth
Kalorama’s trusted information-gathering process provides the most accurate study of the market for anti-depressants, anti-anxiety drugs, ADHD treatments and other psychotherapeutic drugs available today. Information and analysis presented in this report is based on extensive interviews with senior management of top companies and in the psychotherapeutics market. While financial reports, major research literature and government information is culled, information is corroborated and key market insights originate from interviews with industry leaders.
Product managers, marketing managers, business development executives, advertising agency or investment firm executives, as well as information and research center librarians are among the individuals who will find this survey of the changing psychotherapeutics market essential.
Kalorama’s Antidepressants, Antipsychotics, Antianxiety Drugs, and other Psychotherapeutics: World Market provides coverage of the following brands:
- Nardil
- Parnate
- Prozac
- Paxil
- Zoloft
- Celexa
- Lexapro
- Effexor and Effexor XR
- Cymbalta
- Wellbutrin and Wellbutrin XL and Wellbutrin SR
- Serzone
- Desyrel
- Remeron
- Symbyax
- Tolvon
- Xanax
- Ativan
- Klonopin
- Valium
- Versed
- BuSpar
- Lexotan
- Paxil/Seroxat and Paxil CR
- Zoloft
- Ritalin
- Focalin and Focalin XR
- Daytrana
- Strattera
- Concerta
- Metadate CD
- Adderall and Adderall XR
- Chantix/Champix
- Zyban
- Accomplia
- Nicotrol
- Subutex
- Campral
- Methodone
- ReVia/Naltrex
- Antabuse
- Narcan
- Vivitrol
- Depade
- YAZ
- SSRIs
- Compazine, Serentil, Stelazine, Thorazine
- Geodon
- Zyprexa
- Risperdal, Risperdal Consta
- Clozaril
- Seroquel
- Abilify
- Lithobid, Eskalith
- Symbyax
- Lamictal
- EMSAM
